**Table S1. Adjusted associations of EOPC with mortality in subgroup analyses**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** |  | **Overall survival (OS)** | **Cancer-specific survival (CSS)** |
| **Median OS, EOPC, mo (IQR)** | **Median OS, AOPC mo (IQR)** | **Adjusted*****P*-value** | **Adjusted****HR (95% CI)** | **Median CSS, EOPC, mo (IQR)** | **Median CSS, AOPC, mo (IQR)** | **Adjusted*****P*-value** | **Adjusted****HR (95% CI)** |
| Adjuvant chemotherapy NoYes | 35 (16-67)55 (31-/) | 26 (18-48)30 (19-85) | 0.249**0.091** | 0.763 (0.481-1.209)0.574 (0.301-1.092) | 36 (21-67)55 (37-/) | 28 (18-48)30 (19-85) | 0.208**0.042** | 0.736 (0.457-1.186)0.496 (0.253-0.974) |
| Adjuvant radiotherapy NoYes | 39 (21-76)44 (34-48) | 34 (20-55)20 (15-33) | 0.1320.101 | 0.735 (0.493-1.097)0.401 (0.134-1.197) | 50 (22-/)44 (34-48) | 34 (20-59)20 (15-33) | 0.0690.101 | 0.678 (0.447-1.030)0.401 (0.134-1.197) |
| N classificationN0N1N2 | 52 (29-/)35 (19-67)31 (17-48) | 35 (20-/)30 (19-40)26 (16-44) | 0.1240.3510.560 | 0.629 (0.349-1.136)0.748 (0.406-1.377)0.788 (0.354-1.754) | 58 (34-/)35 (19-67)31 (22-48) | 38 (20-/)30 (19-40)26 (16-44) | 0.1040.2350.448 | 0.594 (0.317-1.113)0.684 (0.365-1.280)0.728 (0.321-1.651) |
| TNM staging systemIIIIII | NR (34-/)39 (21-67)41 (18-50) | 48 (24-/)26 (16-40)26 (17-44) | 0.525**0.042**0.471 | 0.764 (0.333-1.754)0.566 (0.327-0.980)0.792 (0.420-1.493) | NR (34-/)53 (26-/)41 (22-50) | 48 (25-/)26 (16-40)26 (17-44) | 0.729**0.015**0.284 | 0.860 (0.366-2.021)0.489 (0.276-0.868)0.699 (0.363-1.345) |

AOPC, average-onset pancreatic cancer; CI, confidence interval; EOPC, early-onset pancreatic cancer; HR, hazard ratio; IQR, interquartile range; NR, not reached; TNM, tumor, lymph node, metastasis.